Truist Lowers DexCom (DXCM) PT to $94 Ahead of Q3 MedTech Sector Preview, Maintains Buy Rating

Core Viewpoint - DexCom Inc. is identified as a promising growth stock in the NASDAQ for the next five years, despite a recent price target reduction by Truist analyst Richard Newitter from $102 to $94 while maintaining a Buy rating [1][2]. Group 1: Company Overview - DexCom Inc. specializes in designing, developing, and commercializing continuous glucose monitoring (CGM) systems both in the US and internationally [3]. Group 2: Market Outlook - Truist anticipates healthy revenue and earnings for Q3 2025 across the MedTech sector, although it warns of potential stock volatility [1]. - Stifel has resumed coverage on several MedTech companies, citing an optimistic outlook for sector growth driven by the adoption of CGMs and insulin pumps, particularly highlighting long-term growth opportunities in the CGM market for Type 2 Basal-only and Type 2 Non-insulin patient segments [2].